The U.S. Food and Drug Administration (FDA) will not process Acorda Therapeutics‘ marketing application for Inbrija (CVT-301), intended for the treatment of off-periods in Parkinson’s disease, until certain questions are answered. The FDA’s refusal to accept Acorda’s new drug application (NDA) for Inbrija wasn’t based on safety or efficacy concerns,…
Synthetic 3D protein structures that better mimic those in nature, but are simpler, could help scientists investigate several disorders, including Parkinson’s disease, a study indicates. The research, “Supramolecular Multiblock Copolymers Featuring Complex Secondary Structures,” appeared in the Journal of the American Chemical Society. Dr. Marcus…
Singapore’s National Neuroscience Institute (NNI) and Nanyang Technological University (NTU Singapore) are teaming up to develop new technologies to better diagnose and treat patients with Parkinson’s disease, brain injuries and other neurological conditions. The collaboration aims to develop an artificial intelligence system capable of using computed tomography (CT) scans to accurately…
The first treatment for levodopa-induced dyskinesia — the involuntary and jerky movements that afflict most Parkinson’s disease patients on this common therapy — was approved Thursday, Aug. 24, by the U.S. Food and Drug Administration. The therapy, Gocovri (amantadine) by Adamas Pharmaceuticals, is an long-acting and extended-release capsule, indicated for those…
In-home senior care provider Senior Helpers has purchased Elmhurst, Illinois-based Handle with Care, a company founded by Julie Kastholm and Debbie Russell that has been providing dignified, trusted home care since 2009 to seniors in the greater Chicago area. Handle with Care’s caregivers assist their clients with everyday activities…
Virtual house calls with a neurologist can be as effective as in-person visits for Parkinson’s disease patients, offering convenience and comfort, a clinical trial indicates. The study, “National randomized controlled trial of virtual house calls for Parkinson disease,” was published in the journal Neurology.
The biopharmaceutical company Cavion announced the appointment of a new executive vice president of research and development and chief medical officer to lead efforts advancing therapies based on the company’s T-type calcium channel (Cav3) platform targeting neurological diseases such as Parkinson’s disease (PD). Spyridon “Spyros” Papapetropoulos, MD, PhD, has been named the…
The online Parkinson’s disease community GeneFo and Greg Macpherson, MitoQ‘s CEO, will conduct a free webinar on Aug. 24, at 1 p.m. EST, to shed light on the latest results of mitochondria-targeting therapies and what the future might bring to patients suffering from Parkinson’s and other neurodegenerative diseases. In the webinar, titled…
Brain proteins called granulins — previously thought to be toxic — might play a crucial role in brain health, according to a study that suggests the proteins might be linked to several neurodegenerative diseases, including Parkinson’s. The identification of a new tool to track the proteins allowed Emory University…
The Parkinson’s Foundation will award $1.2 million to early career scientists working on Parkinson’s disease research in 27 new career development and fellowship grants. Xi Chen, PhD, of the Van Andel Research Institute, was called a “standout grand recipient” this year. Chen is using a $100,000 postdoctoral fellowship…
Get regular updates to your inbox.